Journal
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Volume 6, Issue -, Pages 124-134Publisher
CELL PRESS
DOI: 10.1016/j.omtm.2017.06.007
Keywords
-
Categories
Funding
- Spanish Ministry of Economy, Industry and Competitiveness [PTQ-13-06051]
Ask authors/readers for more resources
Replication-defective (RD) recombinant simian virus 40 (SV40)based gene delivery vectors hold a great potential for clinical applications because of their presumed non-immunogenicity and capacity to induce immune tolerance to the transgene products in humans. However, the clinical use of SV40 vectors has been hampered by the lack of a packaging cell line that produces replication-competent (RC) free SV40 particles in the vector production process. To solve this problem, we have adapted the current SV40 vector genome used for the production of vector particles and generated a novel Vero-based packaging cell line named SuperVero that exclusively expresses the SV40 large T antigen. SuperVero cells produce similar numbers of SV40 vector particles compared to the currently used packaging cell lines, albeit in the absence of contaminating RC SV40 particles. Our unique SV40 vector platformnamed SVac paves theway to clinically test a whole new generation of SV40-based therapeutics for a broad range of important diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available